Benzinga
Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ: ERNA). “We have generated what we believe to be unprecedented data in the setting of dry age-related macular degeneration, but we want to expand our technology to other areas,” Brian Culley, CEO of Lineage, exclusively told Benzinga. “That’s
Benzinga